SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19

NEXT STORY
Leading BioSciences Announces Top Line Phase 2 Data Demonstrating LB1148 Achieves Primary Endpoint with Statistically Significant Improvement in Bowel Function Following Cardiovascular Surgery
PREV STORY
Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Norwegian Cruise Line Holdings Ltd. Announces Plan for Long-Awaited Return to Cruising in the U.S.

author_avatar
NASDAQ Market News

Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held April 25, 2017

COPENHAGEN, Denmark, April 25, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today ...

author_avatar
NASDAQ Market News

Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens

author_avatar
NASDAQ Market News